MERCK & CO., INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 129.3 USD | -0.59% |
|
+1.35% | +18.59% |
| 13/05 | Merck: phase 3 trial in melanoma halted | CF |
| 13/05 | Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study | DJ |
ETFs positioned on Merck & Co., Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.68% | 7 M€ | +6.22% | - | |
| 0.67% | 205 M€ | -.--% | ||
| 0.67% | 8 M€ | +5.48% | - | |
| 0.67% | 206 M€ | -.--% | ||
| 0.64% | 5 M€ | -.--% | - | |
| 0.62% | 57 M€ | +20.49% | - | |
| 0.61% | 727 M€ | +8.19% | ||
| 0.56% | 7 M€ | +0.11% | - | |
| 0.56% | 50 M€ | +9.46% | ||
| 0.54% | 14 M€ | +16.19% | - | |
| 0.51% | 1 M€ | +3.03% | - | |
| 0.51% | 2,517 M€ | +12.10% | - | |
| 0.50% | 1,166 M€ | +0.26% | - | |
| 0.50% | 607 M€ | +0.05% | - | |
| 0.50% | 25 M€ | +3.50% | - | |
| 0.49% | 283 M€ | +19.39% | ||
| 0.46% | 9 M€ | +9.07% | - | |
| 0.40% | 571 M€ | +6.88% | - | |
| 0.39% | 391 M€ | +8.68% | - | |
| 0.36% | 0 M€ | 0.00% | - | |
| 0.33% | 112 M€ | +4.06% | - |
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
16/05/2024
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
129.3
USD
Average target price
141.6
USD
Spread / Average Target
+9.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.59% | 33TCr | |
| +29.98% | 68TCr | |
| +32.04% | 59TCr | |
| -3.52% | 36TCr | |
| +4.07% | 28TCr | |
| +16.48% | 24TCr | |
| +9.45% | 21TCr | |
| -8.92% | 20TCr | |
| +7.09% | 17TCr | |
| -1.22% | 16TCr |
- Stock Market
- Equities
- MRK Stock
- Funds and ETFs Merck & Co., Inc.